Acrivon Therapeutics Inc. is a clinical stage biopharmaceutical company developing precision oncology medicines which matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon's proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics. The company's lead candidate includes ACR-368. Acrivon Therapeutics Inc. is based in WATERTOWN, Mass.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-77.90M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.03 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -70.14% |
| Return on Assets (Trailing 12 Months) | -61.60% |
| Current Ratio (Most Recent Fiscal Quarter) | 7.99 |
| Quick Ratio (Most Recent Fiscal Quarter) | 7.99 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.02 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.43 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.02 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.88 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 42.85M |
| Free Float | 38.35M |
| Market Capitalization | $89.56M |
| Average Volume (Last 20 Days) | 0.37M |
| Beta (Past 60 Months) | 1.91 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 71.62% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |